menu
    • menu
    [{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"},{"orgOrder":0,"company":"Oscotec","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Cevidoplenib for ITP","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cevidoplenib","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II","graph3":"Oscotec","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oscotec \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Oscotec \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Cevidoplenib

    Menu

    Cevidoplenib

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Oscotec

                            South Korea arrow
                            Discovery on Target
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Designation to Cevidoplenib for ITP

                            Details : SKI-O-703 (cevidoplenib) is a SYK inhibitor, small molecule drug candidate, which is being evaluated for the treatment of patients with immune thrombocytopenia.

                            Brand Name : SKI-O-703

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 21, 2024

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Oscotec

                            South Korea arrow
                            Discovery on Target
                            Not Confirmed

                            Oscotec

                            South Korea arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib

                            Details : SKI-O-592 (cevidoplenib) binds to and inhibits SYK activity, blocking Fc receptor and BCR-mediated signaling in inflammatory cells. This leads to the inhibition of the related inflammatory responses and tissue damage. It is being developed for immune thr...

                            Brand Name : SKI-O-592

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 24, 2023

                            Lead Product(s) : Cevidoplenib

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth